九州通：子公司盐酸异丙嗪注射液获得药品注册证书

Core Viewpoint - The approval of the drug "Isopropamide Iodide Injection" by the National Medical Products Administration is a significant milestone for the company, enhancing its product pipeline and market competitiveness [2] Group 1: Company Developments - The subsidiary of the company, Jingfeng Pharmaceutical, received a drug registration certificate for Isopropamide Iodide Injection, an antihistamine used for skin and mucosal allergies and motion sickness [2] - The company has invested approximately 4.67 million yuan in the research and development of this drug [2] Group 2: Market Implications - The approval of this drug is expected to help the company expand its market share and enrich its injectable product line [2] - There are uncertainties regarding production and sales scale due to factors such as national policies and market environment [2]